Background/aim: In Behçet’s disease (BD), arterial involvement represents a significant clinical challenge associated with serious complications. The present study evaluates the characteristic features, affected vessels, lesion types, treatments, and outcomes in BD patients with nonpulmonary arterial involvement. Materials and methods: Included in this retrospective study were 65 BD patients whose interventions and clinical courses were accessed from medical records. The treatments administered included immunosuppressive (IS) therapies and surgical/endovascular procedures. Fisher’s exact and t-test/Mann–Whitney U test were used for statistical analysis. Results: Fifty-nine of the patients (90.8%) were male. The median (Q1–Q3) follow-up was 4 (2–12.8) years. The most commonly affected vessels were the aorta (n = 21, 32.3%) and the femoral artery (n = 19, 29.2%). Aneurysm (n = 50, 63.2%) and thrombosis (n = 18, 22.7%) were the predominant lesions; 14 (21.5%) patients experienced arterial involvement while receiving IS therapy; and 11 (16.9%) had cardiac involvement. Cyclophosphamide and azathioprine were the most commonly used IS agents. Among the 39 (60%) patients who underwent surgical and/or interventional procedures, 32 (82%) had successful outcomes. A second arterial event was experienced by 15.3% of the sample during follow-up, and a third by 3%. Active disease was noted in nine (13.8%) patients at the time of their last visit, and of the six (9.2%) that died, most had both arterial and cardiac involvement. Conclusion: Arterial involvement in BD mostly presents with aneurysms, especially in men. Surgical interventions in addition to IS therapies are required in approximately 50% of cases. As can be understood from the 15.3% relapse rate in the present study, arterial events are not uncommon, underlining the need for long-term monitoring and sustained IS treatment. Of the 9.2% of cases who died, most had both arterial and cardiac involvement.
15 December 2025 in European Journal of Rheumatology
Immunoglobulin G4–related disease (IgG4-RD) is an immune-mediated fibroinflammatory disorder characterized by mass forming lesions that can result in irreversible organ damage and mortality if ignored. Mixed connective tissue disease (MCTD) is characterized as an overlap of systemic lupus erythematosus (SLE), systemic sclerosis, inflammatory myopathy, and rheumatoid arthritis (RA). While cases of IgG4-RD linked to SLE and RA have been documented, to the authors’ knowledge, there has not been a recorded instance of a patient with IgG4-RD related with MCTD. A patient diagnosed with both MCTD and IgG4-RD is presented. Cite this article as: Kocaayan H, Ediboglu ED, Aydin I, Erdogan N, Akar S. Coincidence of mixed connective tissue disease with immunoglobulin –related disease: A case report. Eur J Rheumatol. 2025, 12 (4), 0043, doi: 10.5152/ eurjrheum.2025.25043.
Patients with ANCA-associated vasculitis (AAV) are at increased risk of osteoporosis due to multiple disease- and treatment-related factors. However, real-world data on osteoporosis screening practices in this population remain limited. The aim of this study was to assess osteoporosis screening practices and the prevalence of reduced bone mineral density (BMD) in patients with AAV using a nationwide registry, and to identify factors associated with osteoporosis. This nationwide, retrospective, web-based study was conducted using the Turkish Vasculitis Study Group (TRVaS) database, including patients diagnosed with AAV between January 2000 and December 2023. Patients were evaluated for osteoporosis screening using dual-energy X-ray absorptiometry (DXA) and categorized according to BMD status. Clinical characteristics and potential risk factors were analyzed, and multivariable logistic regression was performed to identify independent predictors of osteoporosis. A total of 528 patients were included (median age 56 years [interquartile range 43–66]; 57.8% male). Of these, 36.2% underwent DXA screening; among screened patients, 40.8% had osteoporosis and 38.7% had osteopenia. In multivariable analysis, older age (odds ratio [OR] 1.03, p = 0.020) and the presence of at least one additional osteoporosis risk factor (OR 2.25, p = 0.049) were independently associated with osteoporosis. This nationwide registry-based study highlights a gap between the recognized risk of osteoporosis in patients with AAV and its implementation in real-world clinical practice. These findings underscore the need for improved screening and comprehensive bone health management strategies in this population.
8 June 2026 in International Journal of Rheumatic Diseases